Memantina Doc

Memantine hydrochloride, the active ingredient in Memantina Doc, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients, aiming to improve cognition and functional abilities.

GNH USA supplies Memantina Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required and comprehensive regulatory support.

Memantina Doc, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease and related cognitive disorders.

- Alzheimer's disease (mild to moderate): helps maintain cognitive function and daily activities. - Alzheimer's disease (moderate to severe): may support functional abilities and slow decline. - Behavioral symptoms of Alzheimer’s disease: can reduce agitation and improve patient cooperation.

Memantina Doc may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or hard stools. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

When prescribing Memantina Doc, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic dysfunction: monitor liver enzymes and use with caution. - History of seizures: evaluate risk as the drug may lower seizure threshold. - Concomitant use of other NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Memantina Doc can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined use may increase neuropsychiatric side effects. - Ketamine: additive NMDA antagonism can enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce the cognitive benefits of memantine. - Carbamazepine: may lower memantine plasma concentrations, reducing effectiveness. - CNS depressants (e.g., benzodiazepines): may increase sedation and dizziness.